Pausing for Halftime: A Stratified Analysis of Epidemiological Characteristics and Outcomes in CMV-Seropositive Allogeneic HSCT Recipients with Cscmvi before and after Day 100

Valcyte (valganciclovir) - Roche, Tanabe Pharma

Prevymis (letermovir) - Merck (MSD)

Safah Khan; Kristina Nasr; Mohammed Akbar; Zachary Yetmar

Jan 8, 2026